INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $9,000 | -25.0% | 600 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $12,000 | -14.3% | 600 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $14,000 | -6.7% | 600 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $15,000 | -70.0% | 600 | -50.0% | 0.00% | -77.8% |
| Q3 2020 | $50,000 | -12.3% | 1,200 | 0.0% | 0.01% | -18.2% |
| Q2 2020 | $57,000 | -25.0% | 1,200 | 0.0% | 0.01% | -31.2% |
| Q1 2020 | $76,000 | -72.2% | 1,200 | -45.5% | 0.02% | -68.0% |
| Q4 2019 | $273,000 | +28.8% | 2,200 | -31.2% | 0.05% | +19.0% |
| Q3 2019 | $212,000 | -16.9% | 3,200 | 0.0% | 0.04% | -19.2% |
| Q2 2019 | $255,000 | – | 3,200 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |